MET and laryngotracheoesophageal cleft: Yet, the selection of LC patients for a given treatment with KIs is limited to those with known driver mutations, that is, ALK, BRAF, EGFR, ERBB2, KRAS, MET, NTRK, ROS and RET alterations.39